Gilead’s short-term win could come at massive cost to the future of pharmaceutical innovation and to the health of the American public. The U.S. government filed the lawsuit in 2019, alleging ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 13.3% over the past month. The stock hit a new 52-week high of $106.69 in the ...